12/03/2010

Intelence (etravirine) label revised to include new drug-drug interaction information

FDA recently updated Intelence (etravirine) label to include drug-drug interaction information between etravirine and fluconazole, voriconazole, lopinavir/ritonavir tablets and clopidogrel.

The major changes to Section 7 Drug Interactions are summarized below.

In additon the magnitude of the interaction for etravirine in the presence of fluconazole, voriconazole and lopinavir/ritonavir tablets can be found in section 12.3 Pharmacokinetics.

Please also refer to http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022187s003lbl.pdf to view the complete updated label.

Etravirine - fluconazole and voriconazole: Co-administration of etravirine and fluconazole or voriconazole significantly increased etravirine exposures. The amount of safety data at these increased etravirine exposures is limited; therefore, etravirine and fluconazole or voriconazole should be co-adminstered with caution. No dose adjustments of Intelence, fluconazole or voriconazole is needed.

Etravirine - lopinavir/ritonavir tablets: Intelence and Kaletra (lopinavir/ritonavir) tablets can be coadministered without dose adjustment

Etravirine - clopidogrel: Activation of clopidogrel to its active metabolite may be decreased when clopidogrel is co-administered with Intelence. Alternative to clopidogrel should be considered.

Etravirine is a Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) made by Tibotec Therapeutics.

FDA

http://www.fda.gov/

Share this page
Email this page to a friend Share this page on Digg Share this page on StumbleUpon Share this page on del.icio.us Share this page on Reddit Share this page on Facebook More...

DISCLAIMER

The EATG is not responsible for the content of this article. It does not necessarily reflect EATG views or opinions.

FAIR USE NOTICE

The information above may contain copyrighted material which has not always been specifically authorised by the copyright owner. Such material is made available for educational purposes to advance the understanding of scientific, ethical, legal and social issues. It is believed that this constitutes a 'fair use' of any such copyrighted material. This material is distributed without profit via the subscription to the daily digest.
European AIDS Treatmen.../Global HIV News/Treatment/
Print